

Figure S1. Detailed results of flow cytometry. (A) Proportion of cells in the gate was 97.38%. (B) Proportion of cells in each population. The percentage of the mature lymphocyte population was 14.92%, the percentage of the mononuclear cell population was 1.93%, the percentage of the naive and mature granulocytic populations was 20.21%, the percentage of the aberrant cell population was 54.61%, and the percentage of the naive red blood cell population was 5.71%. (C) CD19<sup>+</sup> B-cells accounting for lymphocytes, 12.56%. (D) CD3<sup>+</sup>TCRg/d<sup>+</sup>CD22<sup>+</sup> cells accounting for lymphocytes, 3.86%. (E) CD3<sup>+</sup>CD56<sup>+</sup> cells accounting for lymphocytes, 1.56%. (F) CD3<sup>+</sup>CD57<sup>+</sup> cells accounting for lymphocytes, 14.85%. (G) NK cells accounting for lymphocytes, 15.09%. (H) CD3<sup>+</sup> T cells accounting for lymphocytes, 74.90%. (I) CD3<sup>+</sup>CD4<sup>+</sup>/CD3<sup>+</sup>CD8<sup>+</sup>, 13.06. (J) Kappa/Lambda: 1.4. (K) CD56<sup>+</sup> cells accounting for aberrant cells, 79.80%. PerCP, peridinin-chlorophyll-protein complex; PE, phycoerythrin; APC, allophycocyanin; BV, brilliant violet; V500, V500 annexin V; FSC, forward scatter; SSC, side scatter; TCRg/d, T-cell receptor  $\gamma/\delta$ .




Figure S2. Detailed results of flow cytometry. The aberrant cell population expressed: (A) CD45RA, 89.85%; (B) CD2, 87.32%; (C) CD4, 60.74%; (D) CD103, 31.07%; (E) CD10, 26.35%; and (F) CD7, 100%. PerCP, peridinin-chlorophyll-protein complex; PE, phycoerythrin; APC, allophycocyanin; V500, V500 annexin V.




Figure S3. Detailed results of flow cytometry. The aberrant cell population expressed: (A) TDT, 0.02%; (B) CD3, 0.64%; (C) cCD3, 0.34%; (D) CD303, 70.52%; CD304, 0.01%; and (E) HLA-DR, 99.42%. APC, allophycocyanin; BV, brilliant violet; HLA-DR, human leukocyte antigen DR; TDT, terminal deoxynucleotidyl transferase; V500, V500 annexin V.




Figure S4. Detailed results of flow cytometry. The aberrant cell population expressed: (A) CD123, 74.63%; (B) CD36, 93.21%; (C) TCL1, 89.14%; and (D) TIA-1, 63.37%. PE, phycoerythrin; TCL1, T cell leukemia/lymphoma protein 1; TIA-1, T-cell restricted intracellular antigen 1; V500, V500 annexin V.




Figure S5. Detailed results of flow cytometry. The expression level of each antigen in the aberrant cell population was as follows: (A) CD34, 0.79%; (B) CD99, 0.00%; (C) CD1a, 0.11%; (D) CD13, 5.43%; (E) CD33, 1.46%; and (F) CD117, 1.56%. PerCP, peridinin-chlorophyll-protein complex; PE, phycoerythrin; APC, allophycocyanin; V500, V500 annexin V; BV, brilliant violet.






Figure S6. Detailed results of flow cytometry. The aberrant cell population expressed: (A) CD161, 0.31%; (B) perforin, 0.31%; (C) GranzymeB, 0.06%; (D) CD5, 0.17%; and (E) CD94, 0.07%. PerCP, peridinin-chlorophyll-protein complex; PE, phycoerythrin; APC, allophycocyanin; V500, V500 annexin V; BV, brilliant violet.




Figure S7. Detailed results of flow cytometry. The aberrant cell population expressed: (A) CD26, 0.03%; (B) CD30, 0.30%; (C) CD45RO, 0.86%; (D) CD25, 0.14%; (E) CD38, 0.13%; and (F) CD8, 0.03%. PE, phycoerythrin; APC, allophycocyanin; V500, V500 annexin V.

